Monoepitopic anti-FVIII T-cell response

Sebastien Lacroix-Desmazes1 and Bernard Maillere2
1CENTRE DE RECHERCHE DES CORDELIERS; 2ALTERNATIVE ENERGIES AND ATOMIC ENERGY COMMISSION-SACLKY INSTITUTE OF BIOLOGY AND TECHNOLOGIES

In this issue of Blood, Ettinger et al show that the T-cell response to therapeutic factor VIII (FVIII) in a patient with severe hemophilia A due to a multi–exon F8 deletion was oligoclonal and directed against a single epitope located in the C2 domain of the molecule. They further demonstrated that the HLA-DRB1*01:01-restricted T-cell epitope was recognized by the T cells of 2 other hemophilia A patients with the A2201P missense mutation.1

The involvement of CD4+ T cells in the initiation and persistence of the anti-FVIII immune response has long been suspected based on clinical observations and studies in preclinical models of hemophilia A. Patients with a history of high-titer inhibitors experienced a loss of FVIII inhibitors after infection with HIV; the loss was associated with the drop in CD4+ T-cell counts and absence of an anamnestic immune response upon rechallenge using FVIII concentrates. In FVIII-deficient mice, abrogation of the cross-talk between T cells and antigen-presenting cells (APCs) using antibodies to CD40 ligand (CD154), CD80, or CD86, or using CTLA4-Ig constructs, prevents the formation of inhibitors to FVIII.

The large size of FVIII, however, has hampered studies on the specificity of the immune response to FVIII. The molecule encompasses 2332 amino acids (1383 amino acids in its activated form), providing multiple potential T-cell epitopes. Indeed, >1704 FVIII-derived peptides are predicted as core binding peptides for at least one of the 10 most common HLA-DRB1 alleles (Anastas Pashov, Bulgarian Academy of Science, Sofia, e-mail, 10 August 2016). Early work studied the proliferation and cytokine secretion profiles of CD4+ T lymphocytes from patients and healthy donors stimulated in vitro with FVIII or FVIII-derived peptides.2 Strikingly, no clear difference was found in T-cell responses among healthy individuals, hemophilia A patients with neutralizing antibodies (Nab), or hemophilia A patients without Nab. Moreover, proliferation was found against synthetic peptides from all domains of FVIII. This finding was at odds with the expected role of CD4+ T lymphocytes in the anti-FVIII immune response and meant that future studies should also take into account the enormous diversity of hemophilia-causing genetic abnormalities (large/small deletions, intron inversions, missense/nonsense mutations, small deletions/insertions, splice site mutations).

In keeping with the seminal work by Jacquemin et al,3 the initial characterization of FVIII T-cell epitopes performed by the Pratt laboratory focused on hemophilia A patients with missense mutations with Nab. In such patients, the immune response, at least in its early phase, is directed against the epitope of wild-type therapeutic FVIII that corresponds to the mutated epitope of the patient’s endogenous FVIII.

Using major histocompatibility complex II (MHCII) tetramer-guided epitope mapping, Pratt and colleagues isolated and characterized FVIII-specific T-cell clones from patients with the R593C or A2201P mutations4: the C2 domain-derived peptide 2194-2213 was identified as a dominant HLA-DRB1*01:01-restricted T-cell epitope in 2 brothers with the A2201P mutation.

In the present work, Pratt’s group studied a severe hemophilia A patient with the HLADRB1*01:01/10:10 haplotype and with no trace of circulating endogenous FVIII antigen, who developed anti-FVIII Nab following replacement therapy with exogenous FVIII and failed immune tolerance induction (ITI) protocols (ie, desensitization of the patients with high-dose FVIII). In such patients, the T-cell immune response would be expected to target multiple FVIII epitopes and to involve different T-cell clones (ie, polyclonal). This supposition derives from the large number of predicted T-cell epitopes in therapeutic FVIII (175 in the case of DRB1*01:01), by experiments on HLA-DR transgenic mice5 and by MHC-associated peptide proteomics on FVIII-loaded human monocyte-derived dendritic cells.6

Surprisingly, the FVIII2194-2213 peptide presented on DRB1*01:01 was identified as the unique T-cell epitope in the patient, and the repertoire of FVIII2194-2213 Peptide-specific T cells was extremely restricted in terms of usage of TCRB-encoding genes.
The T-cell response was thus monoepitopic and oligoclonal. Confirmation of such an oligoclonal anti-FVIII T-cell response in all severe hemophilia A patients with Nab would represent a drastic paradigm shift in our understanding of FVIII immunogenicity, and, potentially, of the immunogenicity of large therapeutic proteins in general. The results should however be considered with caution. Only peptides from the A2, C1, and C2 domains, that represent 700 amino acids of the FVIII molecule, were tested, leaving open the possibility that additional T-cell epitopes are present in the A1, B, and A3 domains of FVIII. Besides, the patient underwent (and failed) ITI, which means that he has received large amounts of FVIII for a long period of time. It is unclear how such an intensive antigenic stimulation of the patient’s immune system has impacted the population of FVIII-specific CD4+ T lymphocytes, possibly leading to an “epitope shrinking” of the T-cell response. The inclusion of additional Nab-positive patients preferably sampled before initiation of ITI and demonstration that the FVIII T-cell response is also restricted to unique immunodominant epitopes in the case of patients with other HLA-DR alleles are thus warranted.

Nonetheless, confirmation that, for each HLA allele, a single epitope is the target of effector T cells would encourage deimmunization of FVIII by mutation of key residues in the identified immunodominant T-cell epitopes (see figure). The introduced mutations should obviously be compatible with normal hemostatic functions of FVIII, and with its stability and capacity to be exported from the endoplasmic reticulum.
Inhibitory antibodies against factor VIII C1 domain

Gary E. Gilbert VA BOSTON HEALTHCARE SYSTEM; HARVARD MEDICAL SCHOOL

In this issue of Blood, Batsuli et al demonstrate that pathogenic antibodies against the factor VIII (fVIII) C1 domain are more common than previously appreciated and that they can cause bleeding through a novel mechanism.1

In contrast to most inhibitory antibodies, some anti-C1 domain antibodies increase clearance of fVIII while only modestly affecting fVIII activity. Inhibitory anti-fVIII antibodies are the most serious complication of hemophilia A therapy. Because inhibition of fVIII occurs through a variety of mechanisms, detailed studies of these antibodies has also provided remarkable insights into fVIII biology. Inhibitory antibodies against major epitopes on the A2 and C2 domains have confirmed the clinical importance of fVIII binding to fiXa2 and to a phospholipid surface through the respective domains (see figure panel A).3

Some anti-C1 domain antibodies interfere with uptake of fVIII by scavenger receptors and processing by dendritic cells, identifying a surface involved in clearance.4 One anti-C1 antibody that blocks von Willebrand factor (VWF) binding prolongs plasma circulation to the same extent as VWF, confirming the relationship of the C1 domain to the clearance pathway and indicating the potential of antibodies to prolong circulation of fVIII.5

Most inhibitory antibodies only partially block fVIII activity. A paradox of hemophilia A patient care is that the degree to which inhibitory antibodies inhibit fVIII activity in standard assays has poor predictive value for the risk of bleeding.6,7 Thus, the assays are used to measure the titer of antibodies but not to assess bleeding risk. This lack of correlation indicates that our current fVIII assays do not measure critical components of fVIII function.

Recent studies indicate that most clinically important inhibitory antibodies mature slowly into high-affinity immunoglobulin G4 inhibitors, and lower-affinity forms of these antibodies may be detectable many months prior to clinical bleeding.8 This raises the intriguing possibility that dangerous antibodies might be detected before bleeding occurs. Detecting the risk of bleeding before it occurs will require assay (s) that better measure the risk of bleeding. One approach to improving fVIII activity assays may be to measure platelet-dependent activity rather than, or in addition to, activity on phospholipid vesicles. Our laboratory recently found that fVIII binds to a complex of soluble fibrin and the αIIβ3 integrin on activated platelets rather than to phosphatidylserine. This enabled testing that showed that the degree of inhibition by 2 prototype antibodies varies 10- to 100-fold compared with phospholipid vesicle-based activity.9

Batsuli and coworkers have studied a panel of monoclonal antibodies against the fVIII C1 domain.1 Many of these antibodies recognize epitopes that are at least partially distinct from those that were previously characterized (see figure panel B). These are adjacent to, but distinct from, regions that engage phospholipid membranes and...
Monoepitopic anti-FVIII T-cell response

Sebastien Lacroix-Desmazes and Bernard Mailere